Edwin R Manuel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4599013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. Cancers, 2021, 13, 3565.	3.7	10
2	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Therapy, 2020, 27, 235-245.	4.6	42
3	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nature Communications, 2020, 11, 6121.	12.8	71
4	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines, 2020, 8, 617.	3.2	14
5	Hyaluronidase-Expressing <i>Salmonella</i> Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2020, 19, 706-716.	4.1	26
6	5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma. Frontiers in Immunology, 2020, 11, 538.	4.8	15
7	Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy. Oncotarget, 2020, 11, 3486-3488.	1.8	15
8	Phenotypic Switching of NaÃ ⁻ ve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine, 2019, 8, 1726.	2.4	26
9	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Seminars in Cancer Biology, 2019, 59, 236-250.	9.6	200
10	Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice. PLoS ONE, 2019, 14, e0221810.	2.5	18
11	Utilizing <i>Salmonella</i> to treat solid malignancies. Journal of Surgical Oncology, 2017, 116, 75-82.	1.7	7
12	TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. Journal of Leukocyte Biology, 2017, 102, 423-436.	3.3	47
13	Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer. Pancreatic Disorders & Therapy, 2016, 06, 1-2.	0.3	2
14	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncolmmunology, 2016, 5, e1160184.	4.6	13
15	Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model. PLoS ONE, 2016, 11, e0148139.	2.5	38
16	<i>Salmonella</i> -Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunology Research, 2015, 3, 1096-1107.	3.4	58
17	Effective Cancer Vaccine Platform Based on Attenuated <i>Salmonella</i> and a Type III Secretion System. Cancer Research, 2014, 74, 6260-6270.	0.9	60
18	A road less traveled paved by IDO silencing. OncoImmunology, 2013, 2, e23322.	4.6	13

EDWIN R MANUEL

#	Article	IF	CITATIONS
19	Tumor Growth Control with IDO-Silencing Salmonella—Reply. Cancer Research, 2013, 73, 4592-4593.	0.9	2
20	Survivin the battle against immunosuppression. Oncolmmunology, 2012, 1, 240-241.	4.6	4
21	Systemic Delivery of <i>Salmonella typhimurium</i> Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. Cancer Research, 2012, 72, 6447-6456.	0.9	84
22	Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice. Clinical Cancer Research, 2012, 18, 5628-5638.	7.0	52
23	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunology, Immunotherapy, 2011, 60, 99-109.	4.2	38
24	Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting <i>Salmonella-</i> Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors. Cancer Research, 2011, 71, 4183-4191.	0.9	79
25	Carbon Nanotubes Enhance CpG Uptake and Potentiate Antiglioma Immunity. Clinical Cancer Research, 2011, 17, 771-782.	7.0	147
26	Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression. Journal of Immunotherapy, 2010, 33, 609-617.	2.4	28
27	Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology, 2010, 403, 155-162.	2.4	17
28	Vaccination Reduces Simian-Human Immunodeficiency Virus Sequence Reversion through Enhanced Viral Control. Journal of Virology, 2010, 84, 12782-12789.	3.4	2
29	Diverse Cross-Reactive Potential and VÎ ² Gene Usage of an Epitope-Specific Cytotoxic T-Lymphocyte Population in Monkeys Immunized with Diverse Human Immunodeficiency Virus Type 1 Env Immunogens. Journal of Virology, 2009, 83, 9803-9812.	3.4	1
30	Dominant CD8+ T-Lymphocyte Responses Suppress Expansion of Vaccine-Elicited Subdominant T Lymphocytes in Rhesus Monkeys Challenged with Pathogenic Simian-Human Immunodeficiency Virus. Journal of Virology, 2009, 83, 10028-10035.	3.4	10
31	Mamu-AâŽ01/Kb transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. Virology, 2009, 387, 16-28.	2.4	2
32	Clonal Focusing of Epitope-Specific CD8 ⁺ T Lymphocytes in Rhesus Monkeys following Vaccination and Simian-Human Immunodeficiency Virus Challenge. Journal of Virology, 2008, 82, 805-816.	3.4	11
33	Contribution of T-Cell Receptor Repertoire Breadth to the Dominance of Epitope-Specific CD8 + T-Lymphocyte Responses. Journal of Virology, 2006, 80, 12032-12040.	3.4	28
34	Use of Molecular Beacons for Rapid, Real-Time, Quantitative Monitoring of Cytotoxic T-Lymphocyte Epitope Mutations in Simian Immunodeficiency Virus. Journal of Clinical Microbiology, 2005, 43, 4773-4779.	3.9	9
35	The helix–loop–helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. Oncogene, 2004, 23, 1930-1938	5.9	39
36	Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene, 2004, 23, 8206-8215.	5.9	69